<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30056598</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1432-0851</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>67</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>Cancer immunology, immunotherapy : CII</Title>                <ISOAbbreviation>Cancer Immunol. Immunother.</ISOAbbreviation>            </Journal>            <ArticleTitle>Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3.</ArticleTitle>            <Pagination>                <MedlinePgn>1559-1569</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00262-018-2218-9</ELocationID>            <Abstract>                <AbstractText>Current treatments for tumors expressing epidermal growth factor receptor (EGFR) include anti-EGFR monoclonal antibodies, often used in conjunction with the standard chemotherapy, radiation therapy, or other EGFR inhibitors. While monoclonal antibody treatment is efficacious in many patients, drawbacks include its high cost of treatment and side effects associated with multiple drug infusions. As an alternative to monoclonal antibody treatments, we have focused on peptide-based vaccination to trigger natural anti-tumor antibodies. Here, we demonstrate that peptides based on a region of the EGFR extracellular domain IV break immune tolerance to EGFR and elicit anti-tumor immunity. Mice immunized with isoforms of EGFR peptide p580-598 generated anti-EGFR antibody and T-cell responses. Iso-aspartyl (iso-Asp)-modified EGFR p580 immune sera inhibit in vitro growth of EGFR overexpressing human A431 tumor cells, as well as promote antibody-dependent cell-mediated cytotoxicity (ADCC). Antibodies induced by Asp and iso-Asp p580 bound homologous regions of the EGFR family members HER2 and HER3. EGFR p580 immune sera also inhibited the growth of the human tumor cell line MDA-MB-453 that expresses HER2 but not EGFR. Asp and iso-Asp EGFR p580 induced antibodies were also able to inhibit the in vivo growth of EGFR-expressing tumors. These data demonstrate that EGFR peptides from a region of the EGFR extracellular domain IV promote anti-tumor immunity, tumor cell killing, and antibodies that are cross reactive with ErbB family members.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Doyle</LastName>                    <ForeName>Hester A</ForeName>                    <Initials>HA</Initials>                    <AffiliationInfo>                        <Affiliation>Section of Rheumatology, Yale University School of Medicine, P.O. Box 208031, New Haven, CT, 06520-8031, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Koski</LastName>                    <ForeName>Raymond A</ForeName>                    <Initials>RA</Initials>                    <AffiliationInfo>                        <Affiliation>L2 Diagnostics, New Haven, CT, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bonaf√©</LastName>                    <ForeName>Nathalie</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>L2 Diagnostics, New Haven, CT, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bruck</LastName>                    <ForeName>Ross A</ForeName>                    <Initials>RA</Initials>                    <AffiliationInfo>                        <Affiliation>Section of Rheumatology, Yale University School of Medicine, P.O. Box 208031, New Haven, CT, 06520-8031, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tagliatela</LastName>                    <ForeName>Stephanie M</ForeName>                    <Initials>SM</Initials>                    <AffiliationInfo>                        <Affiliation>Section of Rheumatology, Yale University School of Medicine, P.O. Box 208031, New Haven, CT, 06520-8031, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gee</LastName>                    <ForeName>Renelle J</ForeName>                    <Initials>RJ</Initials>                    <AffiliationInfo>                        <Affiliation>Section of Rheumatology, Yale University School of Medicine, P.O. Box 208031, New Haven, CT, 06520-8031, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mamula</LastName>                    <ForeName>Mark J</ForeName>                    <Initials>MJ</Initials>                    <AffiliationInfo>                        <Affiliation>Section of Rheumatology, Yale University School of Medicine, P.O. Box 208031, New Haven, CT, 06520-8031, USA. mark.mamula@yale.edu.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>CA128165</GrantID>                    <Agency>National Institutes of Health</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>AI48120</GrantID>                    <Agency>National Institutes of Health</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>R01 AI048120</GrantID>                    <Acronym>AI</Acronym>                    <Agency>NIAID NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R41 CA128165</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R42 CA128165</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>28</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Germany</Country>            <MedlineTA>Cancer Immunol Immunother</MedlineTA>            <NlmUniqueID>8605732</NlmUniqueID>            <ISSNLinking>0340-7004</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="D011958">Receptor, Epidermal Growth Factor</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.10.1</RegistryNumber>                <NameOfSubstance UI="D020893">Receptor, ErbB-3</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000072283" MajorTopicYN="N">A549 Cells</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000920" MajorTopicYN="N">Antibody-Dependent Cell Cytotoxicity</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011958" MajorTopicYN="N">Receptor, Epidermal Growth Factor</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D020893" MajorTopicYN="N">Receptor, ErbB-3</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">EGFR</Keyword>            <Keyword MajorTopicYN="N">HER2</Keyword>            <Keyword MajorTopicYN="N">HER3</Keyword>            <Keyword MajorTopicYN="N">Peptide</Keyword>            <Keyword MajorTopicYN="N">Vaccine</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>01</Month>                <Day>12</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>24</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>30</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>30</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30056598</ArticleId>            <ArticleId IdType="doi">10.1007/s00262-018-2218-9</ArticleId>            <ArticleId IdType="pii">10.1007/s00262-018-2218-9</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>